Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication

Cai, Lei; Sun, Yajie; Song, Yi; Li, Xu; Zhang, Dongna; Dou, Yuanyuan; Wang, Hongquan

doi:10.1007/s00705-017-3436-8

Cited by 28 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the submission of our manuscript, several groups independently verified anti-ZIKV activities of favipiravir [ 34 , 35 , 36 , 37 ]. Baz et al screened in vitro susceptibility of different strains of ZIKV to favipiravir and ribavirin.…”

Section: Discussionmentioning

confidence: 99%

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

Kim

Seong

Kumar

et al. 2018

Viruses

View full text Add to dashboard Cite

Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain–Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

Kim

Seong

Kumar

et al. 2018

Viruses

View full text Add to dashboard Cite

show abstract

“…Favipiravir failed to display anti-ZIKV activity in our assay. Lei Cai et al have showed an EC 50 value above 100 µM (EC 50 was 110.9 ± 13.1 µM) for favipiravir, which was the highest compound concentration in our assay [40]. Thus, antiviral activity might have been observed with increased concentration of favipiravir.…”

Section: Discussionmentioning

confidence: 50%

Antiviral Activity of Benzavir-2 against Emerging Flaviviruses

Gwon

Strand

Lindqvist

et al. 2020

Viruses

View full text Add to dashboard Cite

Most flaviviruses are arthropod-borne viruses, transmitted by either ticks or mosquitoes, and cause morbidity and mortality worldwide. They are endemic in many countries and have recently emerged in new regions, such as the Zika virus (ZIKV) in South-and Central America, the West Nile virus (WNV) in North America, and the Yellow fever virus (YFV) in Brazil and many African countries, highlighting the need for preparedness. Currently, there are no antiviral drugs available to treat flavivirus infections. We have previously discovered a broad-spectrum antiviral compound, benzavir-2, with potent antiviral activity against both DNA-and RNA-viruses. Our purpose was to investigate the inhibitory activity of benzavir-2 against flaviviruses. We used a ZIKV ZsGreen-expressing vector, two lineages of wild-type ZIKV, and other medically important flaviviruses. Benzavir-2 inhibited ZIKV derived reporter gene expression with an EC 50 value of 0.8 ± 0.1 µM. Furthermore, ZIKV plaque formation, progeny virus production, and viral RNA expression were strongly inhibited. In addition, 2.5 µM of benzavir-2 reduced infection in vitro in three to five orders of magnitude for five other flaviviruses: WNV, YFV, the tick-borne encephalitis virus, Japanese encephalitis virus, and dengue virus. In conclusion, benzavir-2 was a potent inhibitor of flavivirus infection, which supported the broad-spectrum antiviral activity of benzavir-2.

show abstract

“…The antiviral spectrum of Xofloza includes seasonal influenza strains and influenza strains resistant to oseltamivir, significantly reducing the viral load compared with oseltamivir [128]. T-705 is a new type of RNA polymerase inhibitor which can inhibit a wide range of viruses by directly entering into the viral RNA chain or by binding directly to the viral RNA polymerase domain to block viral RNA chain replication and transcription [129,130]. It has been approved for listing in Japan [131,132].…”

Section: Treatmentmentioning

confidence: 99%

Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season

Jiang

Yao

Zhao

et al. 2020

Microbes and Infection

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to sweep the world, causing infection of millions and death of hundreds of thousands. The respiratory disease that it caused, COVID-19 (stands for coronavirus disease in 2019), has similar clinical symptoms with other two CoV diseases, severe acute respiratory syndrome and Middle East respiratory syndrome (SARS and MERS), of which causative viruses are SARS-CoV and MERS-CoV, respectively. These three CoVs resulting diseases also share many clinical symptoms with other respiratory diseases caused by influenza A viruses (IAVs). Since both CoVs and IAVs are general pathogens responsible for seasonal cold, in the next few months, during the changing of seasons, clinicians and public heath may have to distinguish COVID-19 pneumonia from other kinds of viral pneumonia. This is a discussion and comparison of the virus structures, transmission characteristics, clinical symptoms, diagnosis, pathological changes, treatment and prevention of the two kinds of viruses, CoVs and IAVs. It hopes to provide information for practitioners in the medical field during the epidemic season.

show abstract

Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication

Cited by 28 publications

References 28 publications

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models

Antiviral Activity of Benzavir-2 against Emerging Flaviviruses

Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season

Contact Info

Product

Resources

About